GlassScriptPhysician profile
Daniel S Fusco
NPI 1245235936
$23,162.86
in general payments reported to CMS, 2019-2025
10 companies · $216 in 2025
The $216 reported for 2025 was less than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
See the full distribution for Thoracic Surgery (Cardiothoracic Vascular Surgery)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,659 · 2020: $1,716 · 2021: $716 · 2022: $260 · 2023: $14K · 2024: $3,757 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $14K · Consulting Fee: $2,250 · Food and Beverage: $1,927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $13,635.02 |
| Consulting Fee | $2,250.00 |
| Food and Beverage | $1,926.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $19,542.08 | 2019-2024 | |
| Edwards Lifesciences Corporation | $2,248.69 | 2020-2025 | Mitris Resilia Mitral Valve, Inspiris Resilia Aortic Valve |
| Arthrex, INC. | $848.78 | 2024 | |
| Kairos Surgical INC | $237.37 | 2024 | |
| Abbott Laboratories | $125.34 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $53.16 | 2020-2025 | Lokelma |
| Davol INC. | $44.92 | 2020 | |
| Boston Scientific Corporation | $24.37 | 2020 | |
| Lemaitre Vascular, INC. | $20.19 | 2024 | Pruitt Irrigation Occlusion Catheter |
| Novartis Pharmaceuticals Corporation | $17.96 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Fusco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.